Section 503A governs patient-specific compounding by traditional pharmacies — the channel that produces individualized prescriptions under physician order rather than the bulk-scale 503B outsourcing-facility track. The 503A bulks list and its three-category structure (1, 2, 3) is the lever that decides which active substances pharmacies may legally compound while FDA evaluation is pending.
The 2026 storyline turns on the Category 2 removal of 12 peptides — BPC-157, TB-500, KPV, MOTs-C, GHK-Cu (injectable), and others — that took effect April 23, ahead of the July 23–24 PCAC meeting that will recommend whether seven of those peptides should join the 503A bulks list formally. Holt Law's late-April deep dive on post-Category-2 status laid out the legal exposure that pharmacies still face; FormBlends' 2026 State of Peptides report mapped how state pharmacy boards are drawing different lines, with California issuing 30+ enforcement actions since 2023 and Texas focusing on egregious quality violations.
Stories here cover bulks-list movements, PCAC votes, and state-level enforcement. See #503b, #category-2, and #pcac.
The FDA's Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 at the agency's White Oak campus (Silver Spring, Maryland) reaches its first procedural cutoff next Tuesday: June 30, 2026 is the deadline to register for oral testimony in the public-comment portion of the meeting. Written comments to docket FDA-2025-N-6895 at regulations.gov must arrive by 11:59 PM ET July 22, 2026 (one day before the meeting opens). The Committee will discuss BPC-157, KPV, TB-500, and MOTS-C on Day 1 (July 23) and Emideltide/DSIP, Semax, and Epitalon on Day 2 (July 24). All seven peptides came off FDA Category 2 effective April 23, 2026. PCAC recommendations are advisory: the agency makes the final 503A bulks list decision, and the Hims & Hers (HIMS) stock breakout above $30 reflected market consensus that the July vote will tilt toward eligibility. Lengea Law and PeptideClarity have both published prescriber-facing trackers ahead of the meeting.
The Ohio State Board of Pharmacy released a February 18, 2026 update to its peptide compounding guidance establishing state-specific requirements that layer on top of federal 503A rules. The Ohio guidance requires all compounded peptides to be prepared pursuant to a valid patient-specific prescription from an Ohio-licensed practitioner, with detailed prescription documentation and provider-verification protocols; pharmacies cannot compound peptides on the FDA list of substances withdrawn for safety or effectiveness reasons. The guidance followed late-2025 and early-2026 enforcement actions in which at least three Ohio pharmacies received consent agreements and fines for peptide compounding violations. Together with the Alabama Board of Medical Examiners' May 26 notice prohibiting non-FDA-approved peptide prescribing, Ohio's update establishes a clear state-level enforcement pattern ahead of the July 23-24 PCAC meeting.
Foley & Lardner published a May 2026 client memo translating the FDA's April 22 Category 2 removal of 12 peptides for the compounding-pharmacy audience. Key framing: the removal does not, by itself, place these substances on the 503A bulks list, and the peptides will exist in a regulatory gray zone until the PCAC meets July 23–24 to consider seven of them (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon) and the FDA takes final action — which under standard rulemaking timelines could run more than a year past the meeting. The piece joins the Orrick May 2026 503B GLP-1 memo, the FDA Law Blog Pep(tide) Rally analysis (April 23), Holt Law's California Sherman-Law alert, and the Frier Levitt April peptide update as the legal cluster compounders are reading ahead of the meeting.
FormBlends and the FDA Law Blog 'Pep(tide) Rally' analyses surfaced a state-level compliance map that compounders are now navigating ahead of the July PCAC. California's Board of Pharmacy has issued 30+ enforcement actions against peptide-compounding pharmacies since 2023, scrutinizing both quality and technical regulatory compliance. Texas Board of Pharmacy enforcement has historically focused on egregious quality violations rather than minor technical issues, making the state more accessible for licensed 503A and 503B operations under physician prescription. The gap matters because telehealth platforms route fulfillment through state-by-state pharmacy networks; a CVS or compounder routing decision in 2026 is now a state-policy decision as much as a federal one.
Pharmacy law firm Holt Law published a detailed regulatory analysis of how the FDA's April 22 Category 2 removals interact with state pharmacy boards, 503A vs 503B compounding pathways, and physician prescribing requirements. The analysis emphasizes that Category 2 removal is not the same as 503A bulk-list inclusion, and that compounding pharmacies face material legal risk if they begin producing reclassified peptides before the July 23-24 PCAC meeting. The piece is a working reference for pharmacy operations preparing for the post-PCAC environment.
Effective April 22, BPC-157, TB-500, Semax, Epitalon, MOTS-c and seven other peptides were formally removed from the FDA's 503A Category 2 significant-safety-concerns list after original nominators withdrew submissions. The FDA Pharmacy Compounding Advisory Committee will meet July 23-24 to decide whether to add these peptides to the 503A bulks list, which would restore legal compounding under prescription.